Holen Sie sich die Stockscreener-App
234.21
0.57%
-1.2852
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$235.50
Offen:
$233.58
24-Stunden-Volumen:
64,048
Relative Volume:
0.07
Marktkapitalisierung:
$25.85B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
25.84
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
-2.76%
1M Leistung:
-1.76%
6M Leistung:
+16.16%
1J Leistung:
+28.18%
1-Tages-Spanne:
$232.47
$235.69
1-Wochen-Bereich:
$231.52
$242.00
52-Wochen-Spanne:
$171.18
$247.19
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
234.18 | 25.99B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
603.56 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.21 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
324.81 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
256.66 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
518.88 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
UBS raises Quest Diagnostics stock price target on durable volumes By Investing.com - Investing.com Canada
UBS Adjusts Quest Diagnostics Price Target to $245 From $232, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million - Yahoo Finance
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million - The Motley Fool
Quest Diagnostics stock edges lower near 52-week highs after solid Q2 growth - AD HOC NEWS
Quest Diagnostics stock holds steady as investors await next earnings update - AD HOC NEWS
Man Group takes new $495K stake in Quest Diagnostics as stock nears record high - Dealroom
CEO of Quest Diagnostics (NYSE: DGX) sells 10,000 shares - Stock Titan
Quest Diagnostics Insider Sold Shares Worth $2,427,200, According to a Recent SEC Filing - marketscreener.com
Quest Diagnostics stock gains as investors focus on growth and fair value - AD HOC NEWS
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics stock trades near 52-week high as kidney testing deal lifts valuation - AD HOC NEWS
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) insider plans new sale after June $1.9M trade - Stock Titan
Quest Diagnostics SVP & general counsel sells $5.5m in shares - Investing.com Nigeria
Quest Diagnostics SVP & general counsel sells $5.5m in shares By Investing.com - Investing.com South Africa
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Stock Analysis: Navigating Growth Amidst a Competitive Landscape - DirectorsTalk Interviews
Quest Diagnostics stock holds steady as investors await fresh earnings catalysts - AD HOC NEWS
Quest Diagnostics (NYSE: DGX) holder to sell 22,677 shares - Stock Titan
Humanity Health Inc. And Quest Diagnostics Announce Availability Of Humanity Biological Age Analysis Through questhealth.com - marketscreener.com
Quest Diagnostics brings a $29 biological-age report to the U.S.—no extra blood draw - Stock Titan
Roche's Alzheimer's blood test gets FDA clearance; Quest plans U.S. launch - Stock Titan
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology - Yahoo Finance
Quest Diagnostics stock holds near highs after Q2 beat - Ad-hoc-news.de
Is it the Right Time to Retain DGX Stock in Your Portfolio? - TradingView
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Trillium Asset Management LLC Takes $5.43 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
SGL Investment Advisors Inc. Buys Shares of 27,290 Quest Diagnostics Incorporated $DGX - MarketBeat
Danske Bank A S Buys Shares of 68,561 Quest Diagnostics Incorporated $DGX - MarketBeat
5,500 Shares in Quest Diagnostics Incorporated $DGX Acquired by Glaxis Capital Management LLC - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $944,000 in Quest Diagnostics Incorporated $DGX - MarketBeat
Ceredex Value Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
327,575 Shares in Quest Diagnostics Incorporated $DGX Bought by Advisors Capital Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quest Diagnostics stock extends 2026 rally after Q2 revenue and earnings beat - Ad-hoc-news.de
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Deutsche Bank AG Makes New $124.18 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
BlackRock Inc. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal - Yahoo Finance
Quest Diagnostics stock hits a fresh high as Q2 earnings beat expectations - Ad-hoc-news.de
Quest Diagnostics stock hits all-time high at 240.15 USD - Investing.com
Quest Diagnostics stock hits all-time high at 240.15 USD By Investing.com - Investing.com Canada
M.D. Sass LLC Buys New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Commerzbank Aktiengesellschaft FI Takes $1.42 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Foster & Motley Inc. Makes New $3.51 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Invests $2.26 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Alpine Woods Capital Investors LLC Acquires New Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why - Yahoo Finance
WHOOP opens blood tests to nonmembers and adds a test for signals tied to 50+ cancer types - Stock Titan
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.07%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):